Welcome
Support Centre
10 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The role of radical surgery in advanced epithelial ovarian cancer
ISRCTN ISRCTN62526210
ClinicalTrials.gov identifier
Public title The role of radical surgery in advanced epithelial ovarian cancer
Scientific title
Acronym N/A
Serial number at source OV3006
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Ovarian cancer
Participants - inclusion criteria 1. Histologically confirmed epithelial ovarian cancer
2. Macroscopic residual disease unlikely in surgeon's opinion to be completely debulked without bowel resection or other procedures
3. No attempt to radically debulk
4. No prior chemotherapy or radiotherapy
5. No previous or concurrent malignancy other than non melanomatous skin cancer
6. No haematological or biochemical contra-indication to platinum chemotherapy
7. No contraindication to second laparotomy
8. Available to commence chemotherapy or undergo further surgery within 6 weeks of diagnostic laparotomy
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1990
Anticipated end date 31/12/1995
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Patients are randomised to one of two treatment arms:
1. Arm A: High activity platinum based chemotherapy. The recommended chemotherapy regimen is cyclophosphamide and cisplatin given for a maximum of eight cycles.
2. Arm B: Radical debulking surgery followed by chemotherapy as described above.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cancer Research UK
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Cancer Research UK (CRUK) (UK)
  Address PO Box 123
Lincoln's Inn Fields
  City/town London
  Zip/Postcode WC2A 3PX
  Country United Kingdom
  Tel +44 (0)20 7317 5186
  Fax +44 (0)20 7487 4302
  Email kate.law@cancer.org.uk
  Sponsor website: http://www.cancer.org.uk
Date applied 01/07/2001
Last edited 27/05/2008
Date ISRCTN assigned 01/07/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central